SDIC Securities released a research report on April 19 stating that it gave Zoli Pharmaceutical (300181.SZ) a purchase rating, and the target price was 18.25 yuan. The main reasons for the rating include: 1) the collection volume of Wuling capsules is obvious, and the market space for the entire Wuling series is broad; 2) the increase in national standards and provincial standard filings for formula granules is expected to become an important growth point. (Mainichi Keizai Shimbun)
国投证券4月19日发布研报称，给予佐力药业（300181.SZ）买入评级，目标价格为18.25元。评级理由主要包括：1）乌灵胶囊集采放量明显，整个乌灵系列市场空间广阔；2）配方颗粒国标省标备案增加，有望打造成为重要增长点。（每日经济新闻）
SDIC Securities released a research report on April 19 stating that it gave Zoli Pharmaceutical (300181.SZ) a purchase rating, and the target price was 18.25 yuan. The main reasons for the rating include: 1) the collection volume of Wuling capsules is obv
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated